T L Ten Hagen
Overview
Explore the profile of T L Ten Hagen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
215
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim D, Andres M, Li J, Kajioka E, Miller G, Seynhaeve A, et al.
J Interferon Cytokine Res
. 2001 Dec;
21(11):885-97.
PMID: 11747620
Recent reports have shown that tumor necrosis factor-alpha (TNF-alpha) can augment the effects of radiation against certain tumor types. However, the high concentrations of intravenous infusion of TNF-alpha needed to...
2.
Eggermont A, Ten Hagen T
Curr Oncol Rep
. 2001 Jun;
3(4):359-67.
PMID: 11389822
Isolated limb perfusion (ILP) with melphalan is effective against melanoma in-transit metastases but has failed in the treatment of limb-threatening extremity sarcomas. Tumor necrosis factor-alpha (TNF) has changed this situation...
3.
Ten Hagen T, Eggermont A, Lejeune F
Trends Immunol
. 2001 May;
22(3):127-9.
PMID: 11334026
No abstract available.
4.
de Wilt J, Bout A, Eggermont A, van Tiel S, de Vries M, Ten Hagen T, et al.
Hum Gene Ther
. 2001 Mar;
12(5):489-502.
PMID: 11268282
Cytokine gene transfer using (multiple) intratumoral injections can induce tumor regression in several animal models, but this administration technique limits the use for human gene therapy. In the present studies...
5.
de Wilt J, Soma G, Ten Hagen T, Kanou J, Takagi K, Nooijen P, et al.
Anticancer Res
. 2000 Dec;
20(5B):3491-6.
PMID: 11131652
An isolated limb perfusion model (ILP) using soft tissue sarcoma bearing rats (BN175) was used to study antitumour activity of a tumour necrosis factor alpha mutant (TNF-SAM2) in combination with...
6.
van der Veen A, Ten Hagen T, de Wilt J, van Ijken M, Eggermont A
Anticancer Res
. 2000 Dec;
20(5B):3467-74.
PMID: 11131649
Tumor necrosis factor-alpha is a multifunctional cytokine and its potential as antitumor agent has been extensively investigated for the treatment of cancer: Initial enthusiasm was tempered when systemic treatment with...
7.
de Roos W, de Wilt J, van der Kaaden M, Manusama E, de Vries M, Bout A, et al.
Ann Surg
. 2000 Nov;
232(6):814-21.
PMID: 11088076
Objective: To evaluate the potential of isolated limb perfusion (ILP) for efficient and tumor-specific adenovirus-mediated gene transfer in sarcoma-bearing rats. Summary Background Data: A major concern in adenovirus-mediated gene therapy...
8.
de Wilt J, Manusama E, van Etten B, van Tiel S, Jorna A, Seynhaeve A, et al.
Br J Cancer
. 2000 Oct;
83(9):1176-82.
PMID: 11027431
Nitric oxide (NO) is an important molecule in regulating tumour blood flow and stimulating tumour angiogenesis. Inhibition of NO synthase by L-NAME might induce an anti-tumour effect by limiting nutrients...
9.
Ten Hagen T, van der Veen A, Nooijen P, van Tiel S, Seynhaeve A, Eggermont A
Int J Cancer
. 2000 Aug;
87(6):829-37.
PMID: 10956394
It has previously been demonstrated in the setting of an isolated limb perfusion that application of high-dose TNF-alpha in combination with chemotherapy (melphalan, doxorubicin) results in strong synergistic antitumor effects...
10.
Eggermont A, van Ijken M, van Etten B, van der Sijp J, Ten Hagen T, Wiggers T, et al.
Hepatogastroenterology
. 2000 Aug;
47(33):776-81.
PMID: 10919031
Background/aims: The success of and our extensive experience with TNF alpha-based isolated limb perfusions in patients with unresectable extremity soft tissue sarcomas made us explore the possibilities for a similar...